Human ACE2-coupled Magnetic Beads
背景（Background）
The biotinylated ACE2 protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the SARS-CoV-2 S1 protein/SARS-CoV-2 S protein RBD from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This Human ACE2 coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Human ACE2 protein is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Ser 740(Accession # Q9BYF1-1).
應(yīng)用說(shuō)明（Application）
This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
重構(gòu)方法（Reconstitution）
See Certificate of Analysis (CoA) for detailed instruction.
存儲(chǔ)（Storage）
Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C.
Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
原理（Assay Principles）
Application Method:
a) Reconstitute the Beads following the COA. Wash and re-suspend the beads to a certain concentration by adding your dilution buffer.
b) Add the prepared beads to your samples.
c) Beads can be separated from your samples afterwards using a magnetic plate.
The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
制劑（Formulation）
Please contact us for detailed information.
Contact us for customized product form or formulation.
關(guān)鍵字： ACE2磁珠;ACE2 Beads;Magnetic Beads;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶(hù)超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。